Targeted drug afatinib tested on Hard-to-Treat cancers
NCT ID NCT06385483
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This phase II trial is testing the drug afatinib in 19 patients with advanced solid tumors or lymphomas that have a specific EGFR mutation and have not responded to standard treatments. Afatinib works by blocking the mutated EGFR protein that helps cancer cells grow. The study aims to see how many patients' tumors shrink or stop growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- afatinib
- What this could lead to
- If it works, this could provide a treatment option for patients with certain EGFR-mutated cancers that have stopped responding to standard therapies.
- What could go wrong
- This is a small, early-phase trial with only 19 participants, so results may not apply to all patients. Afatinib can cause side effects like diarrhea and skin rash, and the cancer may still progress.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered donor cells could outsmart relapsed myeloma
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a One-Two drug punch beat back Hard-to-Treat myeloma?
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Experimental antibody drug shows promise for Hard-to-Treat lymphoma